• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Novartis

Novartis

Novartis AG ADR NVS 3 Star

Last Price$84.67Day Change (%)0.31%
Open Price$84.35Day Change ($)0.26
Day Range84.13–84.8952-Week Range67.67–85.23

As of Thu 04/17/2014 04:45 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Novartis Heart Failure Pill Trial Ends Early on Positive Result

    Novartis Heart Failure Pill Trial Ends Early on Positive Result

  2. Novartis Names New Alcon, Sandoz Division Heads

    Novartis Names New Alcon, Sandoz Division Heads

  3. UPDATE: European stocks end mixed on inflation jitters

    UPDATE: European stocks end mixed on inflation jitters

  4. EUROPE MARKETS: European Stocks Pare Gains After Weak Inflation Data

    EUROPE MARKETS: European Stocks Pare Gains After Weak Inflation Data

  5. UPDATE: European stocks pare gains after weak inflation data

    UPDATE: European stocks pare gains after weak inflation data

  6. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

  7. European stocks climb ahead of inflation data

    European stocks climb ahead of inflation data

  8. Dividing The Family Farm

    We don't expect to change our fair value estimate for Novartis NVS after seeing the strong fourth-quarter results the firm reported Thursday. Sales were in line with our expectations, and strong growth in operating income helped Novartis improve its profitability. Growth primarily came from the ...

  9. Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) ...

    Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting

  10. Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of ...

    Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.